Skip to main content

Table 1 Clinical information of MPMs included in both training and validation cohorts

From: Spatially resolved, high-dimensional transcriptomics sorts out the evolution of biphasic malignant pleural mesothelioma: new paradigms for immunotherapy

 

Training set

Validation set

 
 

Overall (N = 8)

Overall (N = 84)

 

Sex

   

F

2 (25.0%)

17 (20.2%)

 

M

6 (75.0%)

67 (79.8%)

 

Age

   

Mean (SD)

73.5 (8.8)

70.6 (8.6)

 

Side

   

Left

2 (25.0%)

29 (35.8%)

 

Right

6 (75.0%)

52 (64.2%)

 

N-Miss

 

3

 

Surgery

   

Biopsy

5 (62.5%)

49 (59.0%)

 

Pleurectomy

3 (37.5%)

34 (41.0%)

 

N-Miss

 

1

 

Histology

   

Epithelioid

0 (0%)

34 (40.5%)

 

Biphasic

8 (100.0%)

32 (38.1%)

 

Sarcomatoid

0 (0%)

18 (21.4%)

 

Stage

   

I

4 (50%)

38 (47.6%)

 

II

0 (0%)

4 (5.0%)

 

III

0 (0%)

7 (8.7%)

 

IV

4 (50%)

31 (38.8%)

 

N-Miss

 

4

 

Death

   

No

2 (25%)

8 (9.6%)

 

Yes

6 (75%)

75 (90.4%)

 

N-Miss

 

1

 

Overall survival (months)

   

Mean (SD)

11.9 (8.1)

20.3 (20.6)

 

N-Miss

 

3

Â